NASDAQ:INSM - Insmed Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $22.49 +1.18 (+5.54 %) (As of 09/24/2018 04:00 PM ET)Previous Close$21.31Today's Range$20.92 - $22.5252-Week Range$18.64 - $33.94Volume1.11 million shsAverage Volume816,843 shsMarket Capitalization$1.64 billionP/E Ratio-7.74Dividend YieldN/ABeta1.31 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex. Its earlier-stage clinical pipeline also includes INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug for rare pulmonary disorders. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey. Receive INSM News and Ratings via Email Sign-up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:INSM CUSIPN/A Webwww.insmed.com Phone908-977-9900 Debt Debt-to-Equity Ratio0.83 Current Ratio14.14 Quick Ratio14.14 Price-To-Earnings Trailing P/E Ratio-7.74 Forward P/E Ratio-5.54 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$4.71 per share Price / Book4.77 Profitability EPS (Most Recent Fiscal Year)($2.89) Net Income$-192,640,000.00 Net MarginsN/A Return on Equity-63.81% Return on Assets-41.10% Miscellaneous Employees214 Outstanding Shares77,040,000Market Cap$1.64 billion Insmed (NASDAQ:INSM) Frequently Asked Questions What is Insmed's stock symbol? Insmed trades on the NASDAQ under the ticker symbol "INSM." How were Insmed's earnings last quarter? Insmed Incorporated (NASDAQ:INSM) issued its quarterly earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.08) by $0.09. View Insmed's Earnings History. When is Insmed's next earnings date? Insmed is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Insmed. What price target have analysts set for INSM? 7 analysts have issued 12 month price targets for Insmed's shares. Their forecasts range from $25.00 to $54.00. On average, they expect Insmed's stock price to reach $39.00 in the next year. This suggests a possible upside of 73.4% from the stock's current price. View Analyst Price Targets for Insmed. What is the consensus analysts' recommendation for Insmed? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insmed. Who are some of Insmed's key competitors? Some companies that are related to Insmed include Alkermes (ALKS), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Ligand Pharmaceuticals (LGND), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), GW Pharmaceuticals PLC- (GWPH), Agios Pharmaceuticals (AGIO), Ultragenyx Pharmaceutical (RARE), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Endo International (ENDP) and Intercept Pharmaceuticals (ICPT). Who are Insmed's key executives? Insmed's management team includes the folowing people: Mr. William H. Lewis, Pres, CEO & Director (Age 49)Ms. Christine A. Pellizzari, Chief Legal Officer (Age 50)Mr. Roger Adsett, Chief Commercial Officer (Age 49)Dr. Paul Streck, Chief Medical Officer (Age 55)Mr. Paolo Tombesi, Chief Financial Officer (Age 54) Who are Insmed's major shareholders? Insmed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Redmile Group LLC (2.64%), Voya Investment Management LLC (1.37%), Northern Trust Corp (1.28%), Emerald Advisers Inc. PA (0.94%), Nexthera Capital LP (0.84%) and Bellevue Group AG (0.55%). Company insiders that own Insmed stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden Jr, Melvin Md Sharoky, Myrtle S Potter and Orlov S Nicole Schaeffer. View Institutional Ownership Trends for Insmed. Which major investors are selling Insmed stock? INSM stock was sold by a variety of institutional investors in the last quarter, including Nexthera Capital LP, Redmile Group LLC, Alps Advisors Inc., WINTON GROUP Ltd, California Public Employees Retirement System and Emerald Advisers Inc. PA. Company insiders that have sold Insmed company stock in the last year include Donald J Hayden Jr and Orlov S Nicole Schaeffer. View Insider Buying and Selling for Insmed. Which major investors are buying Insmed stock? INSM stock was bought by a variety of institutional investors in the last quarter, including Voya Investment Management LLC, American Century Companies Inc., Bellevue Group AG, Macquarie Group Ltd., C WorldWide Group Holding A S, Asymmetry Capital Management L.P., Chartwell Investment Partners LLC and Northern Trust Corp. View Insider Buying and Selling for Insmed. How do I buy shares of Insmed? Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Insmed's stock price today? One share of INSM stock can currently be purchased for approximately $22.49. How big of a company is Insmed? Insmed has a market capitalization of $1.64 billion. The biopharmaceutical company earns $-192,640,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Insmed employs 214 workers across the globe. What is Insmed's official website? The official website for Insmed is http://www.insmed.com. How can I contact Insmed? Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected] MarketBeat Community Rating for Insmed (NASDAQ INSM)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 347 (Vote Outperform)Underperform Votes: 338 (Vote Underperform)Total Votes: 685MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe INSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/24/2018 by MarketBeat.com StaffFeatured Article: What Factors Can Affect Return on Equity?